 Observations effect chimeric monoclonal antibody patients mycosis fungoides Chimeric murine/human monoclonal antibody patients mycosis fungoides Successive patients doses mg antibody week consecutive weeks patients clinical improvement responses short duration Serum levels chimeric antibody function dose dose level antibody biopsied skin lesions antibody positive cells blood significant depletion positive cells Low-level antibody responses mouse Ig variable region human Ig allotypic constant region determinants several patients none clinical significance patients primary antibody T-cell proliferative responses foreign protein test antigen suppression mixed lymphocyte reaction dose levels chimeric monoclonal antibody clinical efficacy mycosis fungoides low level immunogenicity immediate immunosuppressive effects tolerance co-injected antigen